ItMSCs: Phase IIa data

Stemedica’s CardioCell LLC subsidiary reported top-line data from a single-blind, crossover, U.S. Phase IIa trial in 22 chronic heart failure patients with non-ischemic cardiomyopathy and LVEF <=40% s...